This ASX 200 giant is about to wake up from a 3-year slumber. Are you ready?

This healthcare stock has been dormant for quite a while. But one expert reckons it's ready to break out for long-term investors.

| More on:
A man wakes up happy with a smile on his face and arms outstretched.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

A large-cap S&P/ASX 200 Index (ASX: XJO) stock, after not doing much for three years, is about to rocket.

That's the opinion of Fairmont Equities managing director Michael Gable, who said CSL Limited (ASX: CSL)'s one-year forward PE ratio of 28 is at the lower end of its 5-year range.

"With the current multiple looking undemanding in the context of forecast earnings per share growth of ~20% over FY22 to FY25 on a compound annual growth rate (CAGR) basis, we consider CSL to be an attractive investment at current levels."

The CSL share price is still around 16% lower than its pre-COVID high reached in February 2020.

"The large consolidation from the past 3 years could be almost ending and that should lead to the stock resuming its longer-term uptrend," Gable said on the Fairmont blog.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

While the current labels remain an "attractive buy", conviction would be even higher once the stock rockets to the next milestone.

"An upside break above $300 would be the next buy signal."

Why is CSL an exciting long-term buy?

Gable cited some key catalysts on the horizon that could bear fruit for CSL investors.

"We consider the key catalysts for the shares to be: upside risk to gross profit margin expansion for CSL Behring over FY24 and FY25, further progress on the R&D product pipeline, and future results to validate the expected earnings growth contribution from the Vifor acquisition."

Vifor's numbers have already looked very positive, he added.

"Vifor's sales performance in 1H23 surprised on the upside, with CSL re-iterating all prior guidance, including its cost synergy target of US$75 million over three years remaining on track."

While raking in decent earnings from its mature businesses such as plasma collection, CSL is developing new products in the research lab.

"There are several potentially positive catalysts likely to emerge from the R&D product pipeline over the near term."

The four product-in-progress milestones Gable looks forward to are:

  • CSL112: currently in phase III trials, expected to launch early 2024
  • Hemgenix: US launch expected in "the near term"
  • Garadacimab for hereditary angioedema attacks: phase III data to be released soon
  • New plasma collection nomogram trial: expected to start this quarter

CSL shares are currently popular among the professional community. According to CMC Markets, 16 out of 19 analysts are rating it as a buy.

Motley Fool contributor Tony Yoo has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
Broker Notes

3 of the best ASX stocks to buy now with $2,500

These shares are highly rated by the team at Bell Potter.

Read more »

A man in suit and tie is smug about his suitcase bursting with cash.
Broker Notes

2 big-name ASX 200 shares brokers rate as top buys

Let's see which shares could be in the buy zone right now.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

a man in a green and gold Australian athletic kit roars ecstatically with a wide open mouth while his hands are clenched and raised as a shower of gold confetti falls in the sky around him.
Broker Notes

3 Australian shares to buy and hold for the next 5 years

Let's see why analysts think these stocks could be worth holding tightly to for the remainder of the 2020s.

Read more »

A person sitting at a desk smiling and looking at a computer.
Broker Notes

4 ASX tech shares impressing analysts today

Four technology companies featured prominently in Wilson Asset Management's recent investment updates.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Broker Notes

Bell Potter names the best ASX shares to buy

Let's see which shares the broker is bullish on this month.

Read more »

Business man at desk looking out window with his arms behind his head at a view of the city and stock trends overlay.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

I young woman takes a bite out of a burrito n the street outside a Mexican fast-food establishment.
Broker Notes

How much upside does Macquarie see for Collins Foods shares?

The company is scheduled to report on 24 June.

Read more »